Anticancer activity of the intraperitoneal-delivered DFP-10825 the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase on peritoneal disseminated ovarian cancer xenograft model

摘要

IntroductionPeritoneal disseminated ovarian cancer is one of the most difficult cancers to treat with conventional anti-cancer drugs and the treatment options are very limited, although an intraperitoneal (ip) paclitaxel has shown some clinical benefit. Therefore, treatment of peritoneal disseminated ovarian cancer is a highly unmet medical need and it is urgent to develop a new ip delivered drug regulating the fast DNA synthesis.